150 related articles for article (PubMed ID: 325728)
1. Antithymocyte globulin (ATG) dosage and graft survival in renal transplantation.
Kountz SL; Butt KH; Rao TK; Zielinski CM; Rafi M; Schultz JR
Transplant Proc; 1977 Mar; 9(1):1023-5. PubMed ID: 325728
[No Abstract] [Full Text] [Related]
2. Use of an antiglobulin-ATG reagent for detection of low levels of alloantibody-improvement of allograft survival in presensitized recipients.
Fuller TC; Cosimi AB; Russell PS
Transplant Proc; 1978 Jun; 10(2):463-6. PubMed ID: 354136
[No Abstract] [Full Text] [Related]
3. Individualized monitoring and modulation of immune reactivity using standardized antithymocyte globulin (ATG).
Thomas F; Mendez-Picon G; Thomas J; Lee HM
Transplant Proc; 1979 Jun; 11(2):1429-30. PubMed ID: 382531
[No Abstract] [Full Text] [Related]
4. Randomized clinical trial of antithymocyte globulin in cadaver renal allograft recipients: importance of T cell monitoring.
Cosimi AB; Wortis HH; Delmonico FL; Russell PS
Surgery; 1976 Aug; 80(2):155-63. PubMed ID: 781887
[TBL] [Abstract][Full Text] [Related]
5. The adjunctive value of equine antithymocyte membrane globulin in a randomized study of patients undergoing cadaveric renal transplantation.
Diethelm AG; Blackstone E; Whelchel JD; Pass RF; Chambers L; Phillips SJ; Thiry C
Transplant Proc; 1979 Mar; 11(1):27-30. PubMed ID: 377644
[No Abstract] [Full Text] [Related]
6. Treatment of acute rejection of renal allografts with antithymocyte globulin or high-dosage prednisone. Influence of recipient DRw6 and DR matching.
Hoitsma AJ; Van Lier HJ; Reekers P; Koene RA
Neth J Med; 1985; 28(6):239-42. PubMed ID: 3892324
[No Abstract] [Full Text] [Related]
7. Low-dose cyclosporine and antithymocyte globulin improve renal allograft survival in highly sensitized patients.
Palmer A; Bewick M; Welsh K; Snowden S; Parsons V; Taube D
Transplant Proc; 1988 Jun; 20(3 Suppl 3):198-200. PubMed ID: 3291241
[No Abstract] [Full Text] [Related]
8. A prospective randomized comparison of antilymphoblast globulin versus antithymocyte globulin for cadaver kidney transplantation.
Toledo-Pereyra LH; Bergren C; Mittal VK; Whitten JI; Baskin S; McNichol L
Transplantation; 1985 Oct; 40(4):448-50. PubMed ID: 3901446
[No Abstract] [Full Text] [Related]
9. Antithymocyte globulin in cadaver renal grafts: prophylaxis and antirejection therapy with three different preparations.
MacDonald AS; Belitsky P; Lannon SG; Cohen A; White J
Transplant Proc; 1982 Dec; 14(4):631-4. PubMed ID: 6762719
[TBL] [Abstract][Full Text] [Related]
10. Superior renal allograft survival and decreased rejection with early high-dose and sequential multi-species antilymphocyte globulin therapy.
Thomas F; Cunningham P; Thomas J; Gross U; Gaskins D; Sash C; Parker K
Transplant Proc; 1987 Feb; 19(1 Pt 3):1874-8. PubMed ID: 3547892
[No Abstract] [Full Text] [Related]
11. Differential effects of horse ATG and rabbit ATG on T cell and T cell subset levels measured by monoclonal antibodies.
Thomas FT; Griesedieck C; Thomas J; Carver M; Whitley T; Warren R; Williams D
Transplant Proc; 1984 Dec; 16(6):1561-3. PubMed ID: 6239426
[No Abstract] [Full Text] [Related]
12. Treatment of steroid-resistant rejections with ATG and/or plasma filtration improves graft survival rates after cadaveric kidney transplantation.
Fassbinder W; Bechstein PB; Stutte HJ; Scheuermann EH; Hanke P; Knöner M; Dathe G; Jonas D; Schoeppe W
Neth J Med; 1985; 28(6):265-7. PubMed ID: 3892329
[No Abstract] [Full Text] [Related]
13. In vivo - in vitro correlates of antithymocyte globulin (ATG) immunosuppression in the human.
Thomas F; Berry R; Mendez-Picon G; Thomas J; Lower RR; Lee HM
Proc Clin Dial Transplant Forum; 1978 Nov 18-20; 8():56-61. PubMed ID: 386321
[No Abstract] [Full Text] [Related]
14. Immunologic monitoring of antithymocyte globulin treatment for acute allograft rejection.
Delmonico FL; Nelson PW; Colvin RB; Cosimi AB
Transplant Proc; 1984 Dec; 16(6):1492-3. PubMed ID: 6390852
[No Abstract] [Full Text] [Related]
15. HLA-D antigen disparity and HLA-DRw antibodies in intrafamilial renal allograft survival.
Cochrum K; Hanes D; Van Speybroeck J; Perkins H; Ferrone S; Indeveri F; Amend W; Vincenti F; Feduska N; Salvatierra O
Transplant Proc; 1979 Mar; 11(1):404-10. PubMed ID: 156426
[No Abstract] [Full Text] [Related]
16. Effects of different ATG (ATGAM) regimens on levels of rosette-forming cells (RFC), serum horse IgG (HoI), and anti-horse antibodies in kidney transplant patients.
Satoh P; Elberg A; Davis J; Uittenbogaart C; Fine R; Hardy MA
Transplant Proc; 1979 Jun; 11(2):1427-8. PubMed ID: 382530
[No Abstract] [Full Text] [Related]
17. Histocompatibility-dependent long-term islet of Langerhans survival induced by antithymocyte globulin.
Beyer MM; Friedman EA
Transplant Proc; 1979 Jun; 11(2):1436-9. PubMed ID: 112739
[No Abstract] [Full Text] [Related]
18. Antithymocyte globulin therapy after renal transplantation at the Massachusetts General Hospital.
Delmonico FL
Transplant Proc; 1984 Aug; 16(4):979-82. PubMed ID: 6380062
[No Abstract] [Full Text] [Related]
19. Relationship of rabbit ATG serum clearance rate to circulating T-cell level, rejection onset, and survival in cardiac transplantation.
Bieber CP; Griepp RB; Oyer PE; David LA; Stinson EB
Transplant Proc; 1977 Mar; 9(1):1031-6. PubMed ID: 325730
[No Abstract] [Full Text] [Related]
20. Clinical immunosuppression with antilymphocyte globulin.
Stiller CR
Can Med Assoc J; 1976 Dec; 115(12):1190-1. PubMed ID: 793703
[No Abstract] [Full Text] [Related]
[Next] [New Search]
